NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

Исследовательская система NIA-AA: на пути к биологическому определению болезни Альцгеймера
Billy Dunn, Philip Scheltens, Clifford R. Jack, María C. Carrillo, Creighton H. Phelps, Thomas J. Montine, José Luís Molinuevo, David Alan Bennett, Frank Jessen, Eliezer Masliah, Kaj Blennow, David M. Holtzman, Thomas Jude Montine, Reisa Anne Sperling, Heather M. Snyder, Christopher Cleon Rowe, William J. Jagust, Samantha Budd Haeberlein, Jason H. Karlawish, Enchi Liu, Katherine P. Rankin, Eric Siemers, Contributors, Cerise L. Elliott, Laurie M. Ryan, Nina B. Silverberg
2018-04-01

AT(N) classification systemAlzheimer's disease biomarkersNIA-AA Research Frameworkbiological definition of Alzheimer's diseasepathologic tau
In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer's disease. Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer's Association to update and unify the 2011 guidelines. This unifying update is labeled a "research framework" because its intended use is for observational and interventional research, not routine clinical care. In the National Institute on Aging and Alzheimer's Association Research Framework, Alzheimer's disease (AD) is defined by its underlying pathologic processes that can be documented by postmortem examination or in vivo by biomarkers. The diagnosis is not based on the clinical consequences of the disease (i.e., symptoms/signs) in this research framework, which shifts the definition of AD in living people from a syndromal to a biological construct. The research framework focuses on the diagnosis of AD with biomarkers in living persons. Biomarkers are grouped into those of β amyloid deposition, pathologic tau, and neurodegeneration [AT(N)]. This ATN classification system groups different biomarkers (imaging and biofluids) by the pathologic process each measures. The AT(N) system is flexible in that new biomarkers can be added to the three existing AT(N) groups, and new biomarker groups beyond AT(N) can be added when they become available. We focus on AD as a continuum, and cognitive staging may be accomplished using continuous measures. However, we also outline two different categorical cognitive schemes for staging the severity of cognitive impairment: a scheme using three traditional syndromal categories and a six-stage numeric scheme. It is important to stress that this framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms. We appreciate the concern that this biomarker-based research framework has the potential to be misused. Therefore, we emphasize, first, it is premature and inappropriate to use this research framework in general medical practice. Second, this research framework should not be used to restrict alternative approaches to hypothesis testing that do not use biomarkers. There will be situations where biomarkers are not available or requiring them would be counterproductive to the specific research goals (discussed in more detail later in the document). Thus, biomarker-based research should not be considered a template for all research into age-related cognitive impairment and dementia; rather, it should be applied when it is fit for the purpose of the specific research goals of a study. Importantly, this framework should be examined in diverse populations. Although it is possible that β-amyloid plaques and neurofibrillary tau deposits are not causal in AD pathogenesis, it is these abnormal protein deposits that define AD as a unique neurodegenerative disease among different disorders that can lead to dementia. We envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD, as well as the multifactorial etiology of dementia. This approach also will enable a more precise approach to interventional trials where specific pathways can be targeted in the disease process and in the appropriate people.
1
Alzheimer’s disease is conceptualized as a continuum, with cognitive severity assessable using continuous measures or categorical three-stage syndromal and six-stage numeric schemes.
2
The AT(N) system can incorporate additional biomarkers within existing categories and introduce new biomarker groups as they become available.
3
The NIA-AA Research Framework updates and unifies prior 2011 recommendations for Alzheimer’s disease research across preclinical, mild cognitive impairment, and dementia stages.
4
The framework classifies biomarkers into amyloid deposition, pathological tau, and neurodegeneration categories, forming the flexible AT(N) system.
5
The framework is intended for observational and interventional research to provide a common language for testing interactions among pathological processes, not for routine clinical care.
6
Within this research framework, Alzheimer’s disease is defined biologically by underlying pathological processes documented through postmortem examination or in vivo biomarkers, rather than clinical symptoms.

Alzheimer's disease defined biologically by underlying pathologic processes detectable by biomarkers (β-amyloid deposition, pathologic tau, neurodegeneration) in living persons

Biomarker-based biological definition, classification, and cognitive staging of Alzheimer’s disease, including interactions among amyloid deposition, pathological tau, neurodegeneration, and cognitive impairment

Publication Details
Publication Date
2018-04-01
Journal
Publisher
ISSN
Cited by
11886
Access Type
Author Information
Authors
Billy Dunn
Philip Scheltens
Clifford R. Jack
María C. Carrillo
Creighton H. Phelps
Thomas J. Montine
José Luís Molinuevo
David Alan Bennett
Frank Jessen
Eliezer Masliah
Kaj Blennow
David M. Holtzman
Thomas Jude Montine
Reisa Anne Sperling
Heather M. Snyder
Christopher Cleon Rowe
William J. Jagust
Samantha Budd Haeberlein
Jason H. Karlawish
Enchi Liu
Katherine P. Rankin
Eric Siemers
Contributors
Cerise L. Elliott
Laurie M. Ryan
Nina B. Silverberg
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%